Showing Results for
- Academic Journals (34)
Search Results
- 34
Academic Journals
- 34
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): Jonathan Foox 1 2 , Scott W. Tighe 3 , Charles M. Nicolet 4 , Justin M. Zook 5 , Marta Byrska-Bishop 6 , Wayne E. Clarke 6 , Michael M. Khayat 7 8 , Medhat Mahmoud 7 8 , Phoebe K. Laaguiby 3 , Zachary T....
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor Affiliations: Stan Crooke rose from poverty to found a company that pioneered antisense drugs. After decades of struggle and years of public doubt, the company created a treatment that has saved thousands of...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedIntegrating synthetic biology into wearables could expand opportunities for noninvasive monitoring of physiological status, disease states and exposure to pathogens or toxins. However, the operation of synthetic circuits...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): Gilad Yaakov 1 , Felix Jonas 1 , Naama Barkai 1 Author Affiliations: (1) Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel Correction to: Nature Biotechnology...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedExisting compendia of non-coding RNA (ncRNA) are incomplete, in part because they are derived almost exclusively from small and polyadenylated RNAs. Here we present a more comprehensive atlas of the human transcriptome,...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): Lucia Lorenzi 1 2 , Hua-Sheng Chiu 3 , Francisco Avila Cobos 1 2 , Stephen Gross 4 , Pieter-Jan Volders 1 2 5 , Robrecht Cannoodt 1 2 6 7 8 , Justine Nuytens 1 2 , Katrien Vanderheyden 1 2 , Jasper Anckaert 1...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedRapid advances in nanopore technologies for sequencing single long DNA and RNA molecules have led to substantial improvements in accuracy, read length and throughput. These breakthroughs have required extensive...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor Affiliations: Bluebird Bio has earned a marketing authorization from the European Commission for its single-dose gene therapy Skysona (elivaldogene-autotemcel; Lenti-D) to treat a severe form of...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedRNA modifications, such as N.sup.6-methyladenosine (m.sup.6A), modulate functions of cellular RNA species. However, quantifying differences in RNA modifications has been challenging. Here we develop a computational...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedEarly results promise a one-off treatment, but gene-editing and gene therapies will have to show durable protection and be affordable to the many patients with sickle cell disease in the world. Author(s): Cormac...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedCanonical CRISPR-knockout (KO) screens rely on Cas9-induced DNA double-strand breaks (DSBs) to generate targeted gene KOs. These methodologies may yield distorted results because DSB-associated effects are often falsely...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): Laura DeFrancesco 1 Author Affiliations: (1) Senior Editor, Nature Biotechnology, Zydus Cadila Healthcare's COVID-19 vaccine--the world's first DNA vaccine approved for humans--got the nod in the form of...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): Nisarg J. Shah 1 2 3 4 9 , Angelo S. Mao 1 2 , Ting-Yu Shih 1 2 , Matthew D. Kerr 1 2 9 , Azeem Sharda 3 4 5 , Theresa M. Raimondo 1 2 , James C. Weaver 2 , Vladimir D. Vrbanac 6 7 , Maud Deruaz 6 7 , Andrew...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedRecent moves of note in and around the biotech and pharma industries. Author Affiliations: Digital healthcare company Cleerly has appointed Brandon Atkinson (photo, left) as chief operating officer and Nick Nieslanik...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): Laura DeFrancesco 1 Author Affiliations: (1) Senior Editor, Nature Biotechnology, It was an up and down quarter for biotech stocks; the pace of financing as a whole slowed, with follow-on financings of...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedWith supply-chain shortages and production problems exacerbating vaccine inequity, global manufacturing must expand to ensure the world's poorest nations are better served. Author Affiliations: As the one-year...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAuthor(s): John J. Cohrssen 1 , Henry I. Miller 2 Author Affiliations: (1) Arlington, USA (2) The Pacific Research Institute, San Francisco, USA To the Editor -- This year marks the 35th anniversary of the US...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedRecent patents relating to methods of delivering RNA, protein and antibody therapeutics. Author Affiliations: US 11,123,554 A method and system for delivering a molecule such as a vaccine or therapeutic to a...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedAdenine base editors (ABEs) catalyze specific A-to-G conversions at genomic sites of interest. However, ABEs also induce cytosine deamination at the target site. To reduce the cytosine editing activity, we engineered a...
-
From:Nature Biotechnology (Vol. 39, Issue 11) Peer-ReviewedLive cell imaging with high spatiotemporal resolution and high detection sensitivity facilitates the study of the dynamics of cellular structure and function. However, extracting high-resolution 4D (3D space plus time)...